Gilead Sciences has signed non-exclusive licensing agreements with 5 generic pharma manufacturers to further expand supply of antiviral drug Remdesivir to treat COVID-19. These include 3 Indian companies; Cipla, Hetero Labs and Jubilant Life Sciences.

It also licensed to Mylan and Pakistan-based Ferozsons Laboratories to manufacture Remdesivir for distribution in 127 countries across the world. Mylan is a US-based generic company with a huge manufacturing base in India. Under the agreement, the companies will receive technology transfer of Gilead manufacturing process for Remdesivir to enable scaling up production quickly.

The 3 licensees can also set their prices for the generic product they produce. The licenses will be royalty-free until the World Health Organization (WHO) declares the end of the Public Health Emergency regarding COVID-19. '

This could be a good sentimental booster for these Indian companies.